The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening

Urology

Volumn 91, Issue , 2016, Pages 12-18

  Vickers, Andrew J ^a   Eastham, James A ^a   Scardino, Peter T ^a   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CENTER; CANCER MORTALITY; CANCER SCREENING; CLINICAL DECISION MAKING; DIGITAL RECTAL EXAMINATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; AGED; BIOPSY; BLOOD; EARLY CANCER DIAGNOSIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; STANDARDS;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84960982124     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.12.054     Document Type: Article

References (25)

1. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
2. J. Walz, A. Gallina, P. Perrotte, and et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer BJU Int 100 2007 1254 1258
3. AGREE Collaboration Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project Qual Saf Health Care 12 2003 18 23
4. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, and et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
5. I.M. Thompson, D.P. Ankerst, Chi C., and et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
6. H. Lilja, D. Ulmert, T. Bjork, and et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436
7. S. Loeb, H.B. Carter, W.J. Catalona, and et al. Baseline prostate-specific antigen testing at a young age Eur Urol 61 2012 1 7
8. A.J. Vickers, D.D. Sjoberg, D. Ulmert, and et al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen BMC Med 12 2014 26
9. J.A. Eastham, E. Riedel, P.T. Scardino, and et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations JAMA 289 2003 2695 2700
10. A.J. Vickers, A.M. Cronin, M.J. Roobol, and et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group Clin Cancer Res 16 2010 4374 4381
11. J.A. Lane, J.L. Donovan, M. Davis, and et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial Lancet Oncol 15 2014 1109 1118
12. A. Vickers, C. Bennette, G. Steineck, and et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial Eur Urol 62 2012 204 209
13. T.J. Wilt, M.K. Brawer, K.M. Jones, and et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
14. R.L. Gruen, V. Pitt, S. Green, and et al. The effect of provider case volume on cancer mortality: systematic review and meta-analysis CA Cancer J Clin 59 2009 192 211
15. Q.D. Trinh, A. Bjartell, S.J. Freedland, and et al. A systematic review of the volume-outcome relationship for radical prostatectomy Eur Urol 64 2013 786 798
16. A.J. Vickers, K. Edwards, M.R. Cooperberg, and et al. A simple schema for informed decision making about prostate cancer screening Ann Intern Med 161 2014 441 442
17. A.J. Vickers, D. Ulmert, D.D. Sjoberg, and et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
18. K. Fall, H. Garmo, O. Andren, and et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer J Natl Cancer Inst 99 2007 526 532
19. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: prostate cancer early detection Version 1 2015
20. H.B. Carter, P.C. Albertsen, M.J. Barry, and et al. Early detection of prostate cancer: AUA guideline J Urol 190 2013 419 426
21. N. Mottet, J. Bellmunt, E. Briers, and et al. Guidelines on prostate cancer Eur Urol 65 2014 124 137
22. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
23. E.A. Vertosick, B.Y. Poon, and A.J. Vickers Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening J Urol 192 2014 724 728
24. S. Carlsson, M. Assel, D. Sjoberg, and et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study BMJ 348 2014 g2296
25. P.J. van Leeuwen, D. Connolly, T.L. Tammela, and et al. Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865